Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya

Infectious Diseases in Obstetrics and Gynecology

Volumn 2015, Issue , 2015, Pages

  Pintye, Jillian ^a   Langat, Agnes ^b   Singa, Benson ^c   Kinuthia, John ^a,d   Odeny, Beryne ^a   Katana, Abraham ^b   Nganga, Lucy ^b   John Stewart, Grace ^a   McGrath, Christine J ^a,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d KENYATTA NATIONAL HOSPITAL   (Kenya)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; BODY WEIGHT; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HEALTH CARE SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KENYA; KENYAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY OUTCOME; PRENATAL GROWTH; PRIORITY JOURNAL; SELF REPORT; TREND STUDY; ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; HIV INFECTIONS; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; RETROSPECTIVE STUDY; VERTICAL TRANSMISSION; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; BIRTH WEIGHT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KENYA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; TENOFOVIR; YOUNG ADULT;

EID: 84956880436     PISSN: 10647449     EISSN: 10980997     Source Type: Journal    
DOI: 10.1155/2015/276851     Document Type: Article

References (40)

1. World Health Organization, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, WHO, Geneva, Switzerland, 2013.
2. World Health Organization, Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations, WHO Library Cataloguing-in-Publication Data, Geneva, Switzerland, 2014.
3. National Institutes of Health, Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the united states," 2012.
4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, Recommendations forUse of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 2012.
5. A. F. Tarantal, A. Castillo, J. E. Ekert, N. Bischofberger, and R. B. Martin, "Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta)," Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 3, pp. 207-220, 2002.
6. K. K. Van Rompay, L. L. Brignolo, D. J. Meyer et al., "Biological effects of short-term or prolonged administration of 9-2-(phosphonomethoxy)propyladenine (tenofovir) to newborn and infant rhesus macaques," Antimicrobial Agents and Chemotherapy, vol. 48, no. 5, pp. 1469-1487, 2004.
7. K. K. A. Van Rompay, L. Durand-Gasselin, L. L. Brignolo et al., "Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects," Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3144-3160, 2008.
8. A. B. Castillo, A. F. Tarantal, M. R. Watnik, and R. BruceMartin, "Tenofovir treatment at 30mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta)," Journal of Orthopaedic Research, vol. 20, no. 6, pp. 1185-1189, 2002.
9. L. Wang, A. P. Kourtis, S. Ellington, J. Legardy-Williams, and M. Bulterys, "Safety of tenofovir during pregnancy for the mother and fetus: a systematic review," Clinical Infectious Diseases, vol. 57, no. 12, pp. 1773-1781, 2013.
10. B. H. Chi, M. Sinkala, F. Mbewe et al., "Single-dose tenofovir and emtricitabine for reduction of viral resistance to nonnucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial," The Lancet, vol. 370, no. 9600, pp. 1698-1705, 2007.
11. E. Arrivé, M.-L. Chaix, E. Nerrienet et al., "Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1," AIDS, vol. 23, no. 7, pp. 825-833, 2009.
12. E. Arrive, M. L. Chaix, E. Nerrienet et al., "Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance," AIDS, vol. 24, no. 16, pp. 2481-2488, 2010.
13. P. M. Flynn, M. Mirochnick, D. E. Shapiro et al., "Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants," Antimicrobial Agents and Chemotherapy, vol. 55, no. 12, pp. 5914-5922, 2011.
14. E. Kinai, S. Hosokawa, H. Gomibuchi, H. Gatanaga, Y. Kikuchi, and S. Oka, "Blunted fetal growth by tenofovir in late pregnancy," AIDS, vol. 26, no. 16, pp. 2119-2120, 2012.
15. C. Q. Pan, L.-J. Mi, C. Bunchorntavakul et al., "Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis b virus infection by highly viremic pregnant women: a case series," Digestive Diseases and Sciences, vol. 57, no. 9, pp. 2423-2429, 2012.
16. R. Beigi, L. Noguchi, T. Parsons et al., "Pharmacokinetics and placental transfer of single-dose tenofovir 1%vaginal gel in term pregnancy," Journal of Infectious Diseases, vol. 204, no. 10, pp. 1527-1531, 2011.
17. F. Sabbatini, F. Prati, V. Borghi, A. Bedini, R. Esposito, and C. Mussini, "Congenitalpyelectasis in childrenborn frommothers on tenofovir containing therapy during pregnancy: report of two cases," Infection, vol. 35, no. 6, pp. 474-476, 2007.
18. D. Nurutdinova, N. F. Onen, E. Hayes, K. Mondy, and E. T. Overton, "Adverse effects of tenofovir use in HIV-infected pregnant women and their infants," Annals of Pharmacotherapy, vol. 42, no. 11, pp. 1581-1585, 2008.
19. A. Viganò, S. Mora, V. Giacomet et al., "In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers," AntiviralTherapy, vol. 16, no. 8, pp. 1259-1266, 2011.
20. A. P. H. Colbers, D. A. Hawkins, A. Gingelmaier et al., "The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women," AIDS, vol. 27, no. 5, pp. 739-748, 2013.
21. Antiretroviral Pregnancy Registry Steering Committee, Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2013, Registry Coordinating Center, Wilmington, NC, USA, 2013.
22. N. R. Mugo, T. Hong, C. Celumet al., "Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial," The Journal of the AmericanMedical Association, vol. 312, no. 4, pp. 362-371, 2014.
23. P. L. Vernazza, I. Graf, U. Sonnenberg-Schwan, M. Geit, and A. Meurer, "Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child," AIDS, vol. 25, no. 16, pp. 2005-2008, 2011.
24. C. E. Ransom, Y. Huo, K. Patel et al., "Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy," Journal of Acquired Immune Deficiency Syndromes, vol. 64, no. 4, pp. 374-381, 2013.
25. G. K. Siberry, P. L. Williams, H. Mendez et al., "Safety of tenofovir use during pregnancy: early growth outcomes inHIVexposed uninfected infants," AIDS, vol. 26, no. 9, pp. 1151-1159, 2012.
26. D. M. Gibb, H. Kizito, E. C. Russell et al., "Pregnancy and infant outcomes among HIV-infected women taking long-term art with and without tenofovir in the DART trial," PLoS Medicine, vol. 9, no. 5, Article IDe1001217, 2012.
27. WorldHealth Organization, WHOChild Growth Standards and the Identification of Severe Acute Malnutrition in Infants and Children: A Joint Statement by the World Health Organization and the United Nations Childrens Fund, World Health Organization, Geneva, Switzerland, 2009.
28. M. B. Duggan, "Anthropometry as a tool for measuring malnutrition: impact of the new WHO growth standards and reference," Annals of Tropical Paediatrics, vol. 30, no. 1, pp. 1-17, 2010.
29. S. Keino, G. Plasqui, G. Ettyang, and B. van den Borne, "Determinants of stunting and overweight among young children and adolescents in sub-Saharan Africa," Food and Nutrition Bulletin, vol. 35, no. 2, pp. 167-178, 2014.
30. R. E. Black, C. G. Victora, S. P. Walker et al., "Maternal and child undernutrition and overweight in low-income and middleincome countries," The Lancet, vol. 382, no. 9890, pp. 427-451, 2013.
31. S. Isanaka, C. Duggan, and W. W. Fawzi, "Patterns of postnatal growth in HIV-infected and HIV-exposed children," Nutrition Reviews, vol. 67, no. 6, pp. 343-359, 2009.
32. H. S. Kruger, "Maternal anthropometry and pregnancy outcomes: a proposal for the monitoring of pregnancy weight gain in outpatient clinics in South Africa," Curationis, vol. 28, no. 4, pp. 40-49, 2005.
33. M. Tadrous, J. J. Gagne, T. Stürmer, and S. M. Cadarette, "Disease risk score as a confounder summary method: systematic review and recommendations," Pharmacoepidemiology and Drug Safety, vol. 22, no. 2, pp. 122-129, 2013.
34. D. Strauss, "On miettinens multivariate confounder score," Journal of Clinical Epidemiology, vol. 51, no. 3, pp. 233-236, 1998.
35. J. Villar, H. E. Knight, M. de Onis et al., "Conceptual issues related to the construction of prescriptive standards for the evaluation of postnatal growth of preterm infants," Archives of Disease in Childhood, vol. 95, no. 12, pp. 1034-1038, 2010.
36. S. Beck, D. Wojdyla, L. Say et al., "The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity," Bulletin of the World Health Organization, vol. 88, no. 1, pp. 31-38, 2010.
37. J. Y. Chen, H. J. Ribaudo, S. Souda et al., "Highly active antiretroviral therapy and adverse birth outcomes among HIVinfected women in botswana," Journal of InfectiousDiseases, vol. 206, no. 11, pp. 1695-1705, 2012.
38. K. van der Merwe, R. Hoffman, V. Black, M. Chersich, A. Coovadia, and H. Rees, "Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study," Journal of the International AIDS Society, vol. 14, no. 1, article 42, 2011.
39. J. Villar, L. Cheikh Ismail, C. G. Victora et al., "International standards for newborn weight, length, and head circumference by gestational age and sex: the newborn cross-sectional study of the intergrowth-21st project," The Lancet, vol. 384, no. 9946, pp. 857-868, 2014.
40. L. F. Johnson, K. Stinson, M.-L. Newell et al., "The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV," Journal of Acquired Immune Deficiency Syndromes, vol. 59, no. 4, pp. 417-425, 2012.